Company:  DYAX CORP (DYAX)
Form Type:  10-K
Filing Date:  3/4/2013 
CIK:  0000907562 
Address:  55 NETWORK DRIVE 
City, State, Zip:  BURLINGTON, Massachusetts 01803-2756 
Telephone:  617-250-5769 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$6.91  
Change: 
0.065 (0.95%)  
Trade Time: 
Apr 24  
Market Cap: 
$937.55M
Description of Business
The principal focus of our efforts is to develop and commercialize treatments for hereditary angioedema and to identify other disorders that are mediated by plasma kallikrein. We developed KALBITOR on our own, and since 2010, we have been selling it in the United States for the treatment of acute attacks of HAE. We are also developing DX-2930, a fully human monoclonal antibody inhibitor of plasma kallikrein, which we believe is a candidate to treat HAE prophylactically. The safety, tolerability, and kallikrein inhibition results of a Phase 1a clinical study in healthy volunteers support advancing the DX-2930 development program into a Phase 1b study in HAE patients in mid-2014. We have also completed development of a biomarker assay that should assist us in detecting the activation of plasma kallikrein in patient blood.
Register for EDGAR Pro and access this filing in:     
  FORM 10-K
    PART I
      ITEM 1. BUSINESS
      ITEM 1A. RISK FACTORS
      ITEM 1B. UNRESOLVED STAFF COMMENTS
      ITEM 2. PROPERTIES
      ITEM 3. LEGAL PROCEEDINGS
      ITEM 4. MINE SAFETY DISCLOSURES
    PART II
      ITEM 5. MARKET FOR THE COMPANY'S COMMON EQUITY, RELATED ...
      ITEM 6. SELECTED CONSOLIDATED FINANCIAL DATA
      ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL ...
        RESULTS OF OPERATIONS
        LIQUIDITY AND CAPITAL RESOURCES
          INCOME STATEMENT
      ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT ...
      ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
        REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
        BALANCE SHEET
        INCOME STATEMENT
        STOCKHOLDERS EQUITY
        CASH FLOW
        Notes to Consolidated Financial Statements
      ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ...
      ITEM 9A. CONTROLS AND PROCEDURES
      ITEM 9B. OTHER INFORMATION
    PART III
      ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
      ITEM 11. EXECUTIVE COMPENSATION
      ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND ...
      ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND ...
      ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES
    PART IV
      ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES
    SIGNATURES
  EXHIBIT 10.7(C)
  EXHIBIT 10.7(D)
  EXHIBIT 10.7(E)
  EXHIBIT 10.8(A)
  EXHIBIT 10.8(B)
  EXHIBIT 21.1
    SUBSIDIARIES
  EXHIBIT 23.1
    CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
  EXHIBIT 31.1
  EXHIBIT 31.2
  EXHIBIT 32.1
    Certification of Periodic Financial Report
BROKERAGE PARTNERS